Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about SLS, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Galinpepimut-S | Acute Myeloid Leukemia | Phase 3 · NCT04229979 | Active not recruiting |
| Nelipepimut-S | Breast Cancer | Phase 2 · NCT02297698 | Completed |
| Tambiciclib (SLS009) | Hematologic Malignancies | Phase 1/2 · NCT04588922 | Recruiting |
Also used in these trials (approved or third-party drugs, not SLS's own candidates): Azacitidine, Cytarabine, Decitabine, Recombinant Granulocyte-Macrophage Colony-Stimulating Factor, Venetoclax, Bortezomib, Trastuzumab, Lenalidomide, Pembrolizumab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
SLS holds $138.3M in cash and short-term investments (as of Jun 30, 2026) and burns about $8.2M/quarter from operations, an estimated runway of 50.5 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 45 · Elevated
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when SLS files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| STATE STREET CORPORATION | Institution (13G, 5%+) | 12,996,558 | 6.44% | 2026-06-30 |
| BlackRock, Inc. | Institution (13G, 5%+) | 12,136,331 | 6.01% | 2026-03-31 |
| Vanguard Capital Management | Institution (13G, 5%+) | 9,666,278 | 4.79% | 2026-06-30 |
| Geode Capital Management, LLC | Institution (13F) | 4,884,175 | 2.42% | 2026-06-30 |
| Anson Funds Management LP | Institution (13F) | 4,500,000 | 2.23% | 2026-06-30 |
| Jones Financial Companies, L.L.L.P. | Institution (13F) | 2,304,561 | 1.14% | 2026-06-30 |
| Vanguard Portfolio Management LLC | Institution (13F) | 2,161,099 | 1.07% | 2026-06-30 |
| Susquehanna International Group, LLP | Institution (13F) | 2,050,597 | 1.02% | 2026-06-30 |
| Angelos M. Stergiou President and CEO, Director · +624,250 options |
Insider | 1,759,183 | 0.87% | 2026-06-16 |
| Northern Trust Corporation | Institution (13F) | 1,619,928 | 0.80% | 2026-06-30 |
| Vanguard Fiduciary Trust Co | Institution (13F) | 1,335,166 | 0.66% | 2026-06-30 |
| UBS Group AG | Institution (13F) | 1,252,757 | 0.62% | 2026-06-30 |
Share count 201,945,709 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-06-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-06-16 filed 2026-06-18 |
Stergiou Angelos M. |
Award (A) | 1,065,000 | – | 1,759,183 |
| 2026-01-07 filed 2026-01-09 |
Varian John |
Award (A) | 50,000 | – | 72,900 |
| 2026-01-07 filed 2026-01-09 |
CICIC DRAGAN |
Award (A) | 300,000 | – | 557,805 |
| 2026-01-07 filed 2026-01-09 |
Burns John Thomas |
Award (A) | 300,000 | – | 554,327 |
| 2026-01-07 filed 2026-01-09 |
Kalin Katherine Bach |
Award (A) | 50,000 | – | 154,400 |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SLS and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →